Fosun Pharmaceutical (02196): The drug registration application for adjuvant indications of citric acid fosciclovir capsules has been approved by the National Medical Products Administration.

Wisdom Financial News APP reported that Fosun Pharma (02196) announced that its controlling subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., recently had its new drug registration application for the drug citrate Fulvestrant capsules (trade name: Futenning, project code: FCN-437c; hereinafter referred to as "the drug") approved by the National Medical Products Administration. The approved indication is for use in HR-positive, HER2-negative locally advanced or metastatic breast cancer in adult patients: in combination with aromatase inhibitors as initial endocrine therapy.